rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RLAY
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Relay Therapeutics at Jefferies: cash, trials and a dual-track push
      10h agoInvesting.comRLAYJEF
      Relay Therapeutics (RLAY) Could Be 26% Undervalued After Third Quarter 2026 Results
      Nov 10Yahoo FinanceRLAY
      Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
      Nov 4Yahoo FinanceRLAY
      Relay Therapeutics earnings in focus as revenue set to surge
      Nov 4Investing.comRLAY
      Earnings to Watch: Relay Therapeutics Inc (RLAY) Q3 2026 -- GF Value Sees 65% Downside
      Nov 3Yahoo FinanceRLAY
      Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

      CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in three upcoming fireside chats in November: Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 4:30 p.m. ETUBS Global Biopharma Conference 2026 on Tuesday, Nov

      Nov 2Yahoo FinanceRLAY
      Relay Therapeutics officer Peter Rahmer sells $14,020 in shares
      Oct 30Investing.comRLAY
      Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
      Oct 28Yahoo FinanceRLAY
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Novartis Ag ADR (NVS-N) from The Globe and Mail including charting and trades.

      Oct 28The Globe and MailRLAY
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

      Oct 24The Globe and MailPALIRLAY
      Rapport Therapeutics Insider Bought Shares Worth $974,278, According to a Recent SEC Filing
      Oct 22Yahoo FinanceRLAY
      Relay: The Recent Market Excitement Ignores The Reality Of Clinical Risks And Patent Cliffs
      Oct 16Seeking AlphaRLAY
      Analysts Are Bullish on Top Healthcare Stocks: Alvotech (ALVO), Relay Therapeutics (RLAY)

      Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailALVOALVOWRLAY
      Relay Therapeutics CFO Catinazzo sells $329k in shares
      Oct 8Investing.comRLAY
      Relay Therapeutics CEO Sanjiv Patel sells $872,401 company stock
      Oct 8Investing.comRLAY
      Relay Therapeutics Insider Sold Shares Worth $872,402, According to a Recent SEC Filing
      Oct 8Yahoo FinanceRLAY
      Relay Therapeutics Insider Sold Shares Worth $329,322, According to a Recent SEC Filing
      Oct 8Yahoo FinanceRLAY
      Relay Therapeutics (RLAY) Stock Looks Fully Priced On Book Value
      Oct 8Yahoo FinanceRLAY
      Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?
      Oct 8Yahoo FinanceRLAY
      Filana Therapeutics Insider Bought Shares Worth $278,132, According to a Recent SEC Filing
      Oct 1Yahoo FinanceRLAY
      X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics

      WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- X-Chem, a global leader in innovative drug discovery services, announced the achievement of a milestone following Relay Therapeutics’ initiation of a Phase 3 clinical trial of a drug candidate developed from a compound identified through an X-Chem DNA-encoded chemical library (DEL) screen. Relay Therapeutics, a leader in cutting-edge approaches to drug discovery, licensed an inhibitor of the oncology target phosphoinositide 3- kinase alpha (Pl3K

      Sep 22Yahoo FinanceRLAY
      Relay Therapeutics at Morgan Stanley conference: multiple shots on goal
      Sep 16Investing.comRLAYMS
      Relay Therapeutics R&D president sells $161,814 in stock
      Sep 9Investing.comRLAY
      Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing

      Sanjiv Patel, Director, President, and CEO, on September 08, 2026, sold 48,199 shares in Relay Thera

      Sep 9Yahoo FinanceRLAY
      Relay Therapeutics at Wells Fargo conference: pipeline nears key tests
      Sep 8Investing.comRLAYWFC
      Relay Therapeutics CFO Sells 17,717 Shares for $350,000 | The Motley Fool

      Catinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.

      Sep 2The Motley FoolRLAY
      Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

      CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September: 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ETMorgan Stanley 24th Annual Global Healthcare Conference on Wednesday

      Sep 1Yahoo FinanceRLAY
      Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m
      Aug 28Investing.comRLAY

      This is the newest page. Registered accounts read further back.